From: ELF5 and DOK7 regulation in anti-estrogen treated cells and tumors
Group | Primary tumor | Second tumor |
---|---|---|
(1) PR+ to PR+ (n = 10) | ||
 Age (±SD), range | 53.8 (±16.9), 37–84 | 61.4 (±16.7), 40–90 |
 Tumor type | DCIS 1; IDC 8; ILC 1 | DCIS 1; IDC 7; ILC 2 |
 Hormonal therapy | Yes = 10 (6 tamoxifen, 4 type unknown) | |
(2) PR+ to PR− (n = 6) | ||
 Age (±SD), range | 54 (±7.8), 42–62 | 63.3 (±7.1), 55–74 |
 Tumor type | DCIS 1; IDC 3; ILC 1; IDC and ILC 1 | DCIS 2; IDC 3; ILC 1 |
 Hormonal therapy | Yes = 6 (4 tamoxifen, 2 aromatase inhibitor) | |
(3) PR− to PR− (n = 8) | ||
 Age (±SD), range | 60.1 (±10.6), 46–79 | 63.3 (±11.1), 48–80 |
 Tumor type | DCIS 1; IDC 7 | DCIS 1; IDC 7 |
 Hormonal therapy | No = 5; Yes = 3 (all tamoxifen) |